Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14229269 | 0.87 | MAPK1 (0.37) | MAPK1CYP19A1KMT2AHPGDTSHR | |
| SCHEMBL4078712 | 0.84 | MAPK1 (0.39) | MAPK1CYP19A1KMT2AHPGDTSHR | |
| SCHEMBL4079490 | 0.83 | ALDH1A1 (0.35) | KMT2AHPGDTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL22650192 | 0.81 | MAPK1 (0.42) | MAPK1KMT2AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL499428 | 0.80 | KMT2A (0.46) | MAPK1KMT2AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL12018040 | 0.79 | CYP19A1 (0.40) | MAPK1CYP19A1KMT2AHPGDTSHR | |
| SCHEMBL4079296 | 0.76 | MAPK1 (0.39) | MAPK1CYP19A1KMT2AHPGDTSHR | |
| SCHEMBL15896085 | 0.76 | KMT2A (0.44) | MAPK1KMT2AHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL17356716 | 0.76 | KMT2A (0.41) | MAPK1KMT2AHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL4082771 | 0.75 | MAPK1 (0.39) | MAPK1CYP19A1KMT2AHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074135-A2 | SILICON DERIVATIVES FOR PET IMAGING | Bayer Schering Pharma AG (DE) | 2009-07-01 | — | — | EP | claimed |
| WO-2008040441-A2 | SILICON DERIVATIVES FOR PET IMAGING | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-10 | — | — | WO | claimed |
| EP-2074135-A2 | SILICON DERIVATIVES FOR PET IMAGING | Bayer Schering Pharma AG (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090035215-A1 | RADIOFLUORINATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | US | disclosed |
| WO-2008040441-A2 | SILICON DERIVATIVES FOR PET IMAGING | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035215-A1 | RADIOFLUORINATION | AFF2, AFF1, NUTF2 | MAPK1 2960/4885CYP19A1 1473/4885KMT2A 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.